URB602 is a monoacylglycerol lipase (MAGL) inhibitor. By inhibiting MAGL, it increases the amount of 2-arachicodonyl glycerol, which is a natural substrate for the cannabinoid receptors. URB602 shows anti-inflammatory properties in mice models, as well as anti-nociceptive properties. It also demonstrates neuroprotective effects in 7-day old rat pups. Pretreatment with URB602 lessened the effect of hypoxia-ischemic brain damage in rat pup models.